ChiCTR2000041142 版本V1.1 版本创建时间2021/02/27 16:15:14 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2000041142 

最近更新日期:

Date of Last Refreshed on:

2020-12-19 13:11:30 

注册时间:

Date of Registration:

2020-12-19 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

张静静医师:请于伦理委员会批准后才开始征募参试者,并与我们联系上传伦理批件 多粘菌素B治疗CRO肺部感染的真实世界研究

Public title:

A real-world study of polymyxin B in the treatment of CRO pulmonary infections

注册题目简写:

静脉联合雾化吸入多粘菌素B治疗CRO肺部感染患者

English Acronym:

Intravenous combined with nebulized polymyxin B in the treatment of CRO pulmonary infection

研究课题的正式科学名称:

多粘菌素B治疗CRO肺部感染的真实世界研究

Scientific title:

A real-world study of polymyxin B in the treatment of CRO pulmonary infections

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

张静静 

研究负责人:

王岗 

Applicant:

Zhang Jingjing 

Study leader:

Wang Gang 

申请注册联系人电话:

Applicant telephone:

+86 18709276159

研究负责人电话:

Study leader's telephone:

+86 18092848496

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

zjflysun@163.com

研究负责人电子邮件:

Study leader's E-mail:

gang_wang@xjtu.edu.cn

申请单位网址(自愿提供):

Applicant website(voluntary supply):

西安交通大学第二附属医院

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

西安交通大学第二附属医院

申请注册联系人通讯地址:

陕西省西安市西五路157号

研究负责人通讯地址:

陕西省西安市西五路157号

Applicant address:

Xi 5 Road, No. 157, Xi'an, Shaanxi Province

Study leader's address:

Xi 5 Road, No. 157, Xi'an, Shaanxi Province

申请注册联系人邮政编码:

Applicant postcode:

710004

研究负责人邮政编码:

Study leader's postcode:

710004

申请人所在单位:

西安交通大学第二附属医院

Applicant's institution:

The Second Affiliated Hospital of Xi'an Jiaotong University

研究负责人所在单位:

西安交通大学第二附属医院

Affiliation of the Leader:

The Second Affiliated Hospital of Xi'an Jiaotong University

是否获伦理委员会批准:

否/No

Approved by ethic committee:

No

伦理委员会批件文号:

Approved No. of ethic committee:

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

Name of the ethic committee:

伦理委员会批准日期:

Date of approved by ethic committee:

2013-08-26 00:00:00

伦理委员会联系人:

Contact Name of the ethic committee:

伦理委员会联系地址:

Contact Address of the ethic committee:

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

西安交通大学第二附属医院

Primary sponsor:

The Second Affiliated Hospital of Xi'an Jiaotong University

研究实施负责(组长)单位地址:

陕西省西安市西五路157号

Primary sponsor's address:

Xi 5 Road, No. 157, Xi'an, Shaanxi Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

陕西

市(区县):

西安

Country:

China

Province:

Shaanxi

City:

Xi’an

单位(医院):

西安交通大学第二附属医院

具体地址:

西五路157号

Institution
hospital:

The Second Affiliated Hospital of Xi'an Jiaotong University

Address:

157 Fifth West Road

经费或物资来源:

研究者自筹

Source(s) of funding:

self-financing

Target disease:

Carbapenem-resistant Organism pulmonary infection

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

队列研究 

Study design:

Cohort study 

研究目的:

研究多粘菌素B治疗碳青霉烯耐药革兰阴性杆菌(Carbapenem-resistant Organism, CRO)肺部感染(包括耐碳青霉烯类铜绿假单胞菌CRPA、耐碳青霉烯类鲍曼不动杆菌CRAB、耐碳青霉烯类肠杆菌科细菌CRE)患者不同给药途径(包括静脉滴注、雾化吸入、静脉滴注联合雾化吸入)的PK/PD及临床疗效。  

Objectives of Study:

By using the different administration method of polymyxin B (including intravenous drip, atomization inhalation, intravenous drip combined atomization inhalation), study the PK/PD change and clinical curative effect of polymyxin B treatment pulmonary infection with Carbapenem-resistant gram-negative bacillus in patients.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

(1)年龄≥18岁;
(2)在CRO肺部感染治疗过程中使用多粘菌素B的患者,且多粘菌素B治疗时间≥72小时;
(3)多次间隔使用多粘菌素B的患者,以第一次使用多粘菌素B治疗时间≥72小时的治疗期为准;
(4)有明确病原菌结果且药敏结果提示对碳青霉烯类抗生素耐药;
(5)自愿加入研究,签署知情同意书,允许研究者将临床数据用于研究分析者。

Inclusion criteria

(1) Age ≥18 years;
(2) Patients treated with polymyxin B during the treatment of CRO pulmonary infection, and the treatment time of polymyxin B ≥72 hours;
(3) For patients receiving polymyxin B at multiple intervals, the treatment period of the first treatment with polymyxin B should be defined as ≥72 hours;
(4) It has clear pathogenic bacteria results and drug sensitivity results indicate that it is resistant to carbapenems antibiotics;
(5) Volunteer to participate in the study and sign informed consent, allowing researchers to use clinical data for study analysts.

排除标准:

(1)妊娠、有妊娠计划或哺乳期妇女;
(2)入住ICU期间行心肺复苏患者;
(3)晚期恶性肿瘤及HIV感染患者;
(4)对多粘菌素B过敏;
(5)有哮喘病史患者;
(6)3个月内正在参加其他临床研究者。

Exclusion criteria:

(1) Women who are pregnant, have planned pregnancy or are breastfeeding;
(2) during the period of stay in ICU patients with cardiopulmonary resuscitation (CPR);
(3) Patients with advanced malignant tumors and HIV infection;
(4) Allergic to polymyxin B;
(5) Patients with a history of asthma;
(6) Participating in other clinical investigators within 3 months.

研究实施时间:

Study execute time:

From 2021-01-01 00:00:00 To 2022-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2021-01-01 00:00:00 To 2022-12-31 00:00:00  

干预措施:

Interventions:

组别:

根据不同给药途径分组

样本量:

200

Group:

grouped according to different administration methods

Sample size:

干预措施:

干预措施代码:

Intervention:

NIl

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

陕西 

市(区县):

西安 

Country:

China 

Province:

Shaanxi 

City:

Xi'an 

单位(医院):

西安交通大学第二附属医院 

单位级别:

三甲教学医院 

Institution
hospital:

The Second Affiliated Hospital of Xi'an Jiaotong University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

陕西 

市(区县):

西安 

Country:

China 

Province:

Shaanxi 

City:

Xi'an 

单位(医院):

西安交通大学第一附属医院 

单位级别:

三甲教学医院 

Institution
hospital:

The First Affiliated Hospital of Xi'an Jiaotong University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

陕西 

市(区县):

西安 

Country:

China 

Province:

Shaanxi 

City:

Xi'an 

单位(医院):

西安医学院第一附属医院 

单位级别:

三级甲等医院 

Institution
hospital:

The First Affiliated Hospital of Xi'an Medical University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

陕西 

市(区县):

西安 

Country:

China 

Province:

Shaanxi 

City:

Xi'an 

单位(医院):

西安医学院第二附属医院 

单位级别:

三级甲等医院 

Institution
hospital:

The Second Affiliated Hospital of Xi'an Medical University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

陕西省 

市(区县):

西安 

Country:

China 

Province:

Shaanxi 

City:

Xi'an 

单位(医院):

西安高新医院 

单位级别:

三级甲等医院 

Institution
hospital:

Xi'an Gaoxin Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

陕西省 

市(区县):

咸阳 

Country:

China 

Province:

Shaanxi 

City:

Xianyang 

单位(医院):

咸阳市第一人民医院 

单位级别:

三级甲等医院 

Institution
hospital:

Xianyang First People's Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

陕西 

市(区县):

西安 

Country:

China 

Province:

Shaanxi 

City:

Xi'an 

单位(医院):

西安市红会医院 

单位级别:

三级甲等医院 

Institution
hospital:

Honghui Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

陕西 

市(区县):

汉中 

Country:

China 

Province:

Shaanxi 

City:

Hanzhong 

单位(医院):

汉中市中心医院 

单位级别:

三级甲等医院 

Institution
hospital:

Hanzhong Central Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

陕西 

市(区县):

汉中 

Country:

China 

Province:

Shaanxi 

City:

Hanzhong 

单位(医院):

三二0一医院 

单位级别:

三级甲等医院 

Institution
hospital:

3201 Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

陕西 

市(区县):

榆林 

Country:

China 

Province:

Shaanxi 

City:

Yulin 

单位(医院):

榆林市第一医院 

单位级别:

三级甲等医院 

Institution
hospital:

The First Hospital of Yulin

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

陕西 

市(区县):

榆林 

Country:

China 

Province:

Shaanxi 

City:

Yulin 

单位(医院):

榆林市第二医院 

单位级别:

三级甲等医院 

Institution
hospital:

The Second Hospital of Yulin

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

陕西 

市(区县):

西安 

Country:

China 

Province:

Shaanxi 

City:

Xi'an 

单位(医院):

西安市胸科医院 

单位级别:

三级甲等医院 

Institution
hospital:

Xi'an Chest Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

陕西 

市(区县):

渭南 

Country:

China 

Province:

Shaanxi 

City:

Weinan 

单位(医院):

渭南市中心医院 

单位级别:

三级甲等医院 

Institution
hospital:

Weinan Central Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

陕西 

市(区县):

商洛 

Country:

China 

Province:

Shaanxi 

City:

Shangluo 

单位(医院):

商洛市中心医院 

单位级别:

三级甲等医院 

Institution
hospital:

Shangluo Central Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

陕西 

市(区县):

西安 

Country:

China 

Province:

Shaanxi 

City:

Xi'an 

单位(医院):

空军军医大学唐都医院 

单位级别:

三甲教学医院 

Institution
hospital:

Air Force Military Medical University Tangdu Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

陕西 

市(区县):

安康 

Country:

China 

Province:

Shaanxi 

City:

Ankang 

单位(医院):

安康市人民医院 

单位级别:

三级甲等医院 

Institution
hospital:

Ankang People's Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

死亡

指标类型:

主要指标

Outcome:

mortality

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

临床治愈

指标类型:

主要指标

Outcome:

clinical cure

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

细菌清除时间

指标类型:

主要指标

Outcome:

bacterial clearance time

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

ICU住院时长

指标类型:

主要指标

Outcome:

Length of ICU stay

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

无创/有创机械通气时间

指标类型:

次要指标

Outcome:

Noninvasive/invasive mechanical ventilation time

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

氧合指数

指标类型:

次要指标

Outcome:

Oxygenation index

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

感染指标变化

指标类型:

次要指标

Outcome:

Change of infection index

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

体温变化

指标类型:

次要指标

Outcome:

Body temperature changes

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肾毒性

指标类型:

副作用指标

Outcome:

nephrotoxicity

Type:

Adverse events

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

抗生素相关性腹泻

指标类型:

副作用指标

Outcome:

Antibiotic-associated diarrhea

Type:

Adverse events

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

用药后皮肤色素沉着

指标类型:

副作用指标

Outcome:

Skin pigmentation

Type:

Adverse events

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

标本中文名:

痰液

组织:

Sample Name:

sputum

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 90 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

不适用

Randomization Procedure (please state who generates the random number sequence and by what method):

Not Applicable

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

2023-12-31

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

2023-12-31

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

采用手机问卷星记录数据,统一导入到excel表格,用统计学方法处理。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Data were recorded by mobile phone questionnaire, imported into Excel and processed by statistical methods.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2020-12-19 13:11:24